Drug DevelopmentRezolute's lead asset, RZ358, is progressing favorably through clinical trials to treat congenital hyperinsulinism, with promising results that may meet significant unmet medical needs.
Financial StabilityWith a strong cash position and no debt, Rezolute is financially equipped to sustain operations and continue its pivotal drug development programs well into the future.
Regulatory MilestoneRezolute has received positive feedback from the FDA, supporting the advancement of RZ358 into late-stage development, which could potentially expedite the path to regulatory approval and market entry.